Last reviewed · How we verify
anticancer medication A01; immune cells IC01 — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
anticancer medication A01; immune cells IC01 (anticancer medication A01; immune cells IC01) — Hangzhou Converd Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| anticancer medication A01; immune cells IC01 TARGET | anticancer medication A01; immune cells IC01 | Hangzhou Converd Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- anticancer medication A01; immune cells IC01 CI watch — RSS
- anticancer medication A01; immune cells IC01 CI watch — Atom
- anticancer medication A01; immune cells IC01 CI watch — JSON
- anticancer medication A01; immune cells IC01 alone — RSS
Cite this brief
Drug Landscape (2026). anticancer medication A01; immune cells IC01 — Competitive Intelligence Brief. https://druglandscape.com/ci/anticancer-medication-a01-immune-cells-ic01. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab